TABLE 1.
Plasma levels of AOP- or NNY-RANTES after 7 days of constant infusion, recovery of CD4+ human T cells, and plasma levels of HIV RNA in hu-PBL-SCID mice treated with CCR5 antagonists
| Expt | Mousea | Day 7 plasma AOP- or NNY-RANTES concn (pM/ml) | Day 14 % CD4+ T cellsb in peritoneal cavity | Day 14 plasma level of HIV RNA (log10 copies/ml) |
|---|---|---|---|---|
| A | AOP-R 1 | 571 | 17.1 | 3.98 |
| AOP-R 2 | 604 | 29.2 | 6.07 | |
| AOP-R 3 | 510 | 27.7 | 3.86 | |
| AOP-R 4 | 157 | 14.3 | 6.72 | |
| Mean ± SE | 460 ± 51 | 22.1 ± 3.7 | 5.16 ± 0.73 | |
| BSA-1 | <0.01 | 3.5 | 7.16 | |
| BSA-2 | <0.01 | 11.9 | 6.06 | |
| BSA-3 | <0.01 | 6.2 | 6.31 | |
| BSA-4 | <0.01 | 4.4 | 6.12 | |
| Mean ± SE | n6.5 ± 1.9 | 6.41 ± 0.25 | ||
| B | NNY 2 R1 | 104 | 86.1 | <2.30c |
| NNY-2 R2 | 86 | <2.30 | ||
| NNY-2 R3 | 110 | 32.7 | 4.72 | |
| NNY-2 R4 | 87 | <2.30 | ||
| NNY-2 R5 | 90 | 47.9 | 4.32 | |
| Mean ± SE | 96 ± 5 | 55.6 ± 15.9 | ||
| BSA-1 | <0.01 | 11.7 | 6.49 | |
| BSA-2 | <0.01 | 12.3 | 6.36 | |
| BSA-3 | <0.01 | 5.12 | ||
| BSA-4 | <0.01 | 6.34 | ||
| Mean ± SE | 12.0 ± 0.3 | 6.08 ± 0.32 | ||
| C | NNY-3 R1 | 62 | ND | <2.30 |
| NNY-3 R2 | 52 | ND | <2.30 | |
| NNY-3 R3 | 156 | ND | <2.30 | |
| NNY-3 R4 | 48 | ND | 6.02 | |
| NNY-3 R5 | 54 | ND | 5.59 | |
| Mean ± SE | 75 ± 20 | |||
| BSA-1 | <0.01 | ND | 4.16 | |
| BSA-2 | <0.01 | ND | 3.83 | |
| BSA-3 | <0.01 | ND | 5.85 | |
| BSA-4 | <0.01 | ND | 4.56 | |
| BSA-5 | <0.01 | ND | 5.21 | |
| Mean ± SE | 4.72 ± 0.36 |
a
Each mouse is individually designated as in Fig. 2. AOP-R or NNY-R means the animal was treated with either AOP- or NNY-RANTES.
b
CD4+ T cells are reported as a percentage of total CD3 T cells recovered from the peritoneal cavity of each animal. ND, not determined.
c
Below the limit of detection of 200 copies/ml.